Mintu Turakhia

Chief Medical & Scientific Officer and Executive Vice President of Product Innovation

iRhythm Technologies, Inc.

Speaker Sessions

September 22, 2023 | 02:15 PM (PST) - 03:15 PM (PST)

About Mintu Turakhia, MD, MS

Dr. Turakhia is an internationally recognized cardiac electrophysiologist, researcher, executive, and leader in digital health and heart rhythm care. He is Chief Medical & Scientific Officer and Executive Vice President of Product Innovation at iRhythm Technologies, Inc, a publicly traded cardiovascular diagnostics and digital health company. He is Professor of Medicine at the Stanford University School of Medicine.

Dr. Turakhia completed his bachelor’s degree at the University of California (UC) Berkeley, MD and master’s degrees at UCSF, and clinical training at Harvard’s Brigham & Women’s Hospital and UCSF. Trained in computer science, medicine, biostatistics, and research, he has over 25 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation, and the creation and commercialization of digital health products.

At Stanford, he is the Founding Director of the Stanford Center for Digital Health, started in 2015, where he led a large multidisciplinary research program in heart rhythm disorders, real-world evidence, clinical trials, and digital health. He has led several large-scale trials of digital health tools and wearables for heart disease, including as co-principal investigator of the landmark Apple Heart Study, enrolling over 400,000 participants, and published in the New England Journal of Medicine. For 14 years, he served as Chief of Cardiac Electrophysiology at the VA Palo Alto Health Care System, where he developed a best-in-class, high volume arrhythmia care program and where he continues to treat patients with arrhythmia procedures.

An elected member of the American Society of Clinical Investigation, Dr. Turakhia has authored over 300 publications and has received over $50 million in research funding as principal investigator. In 2022, he received the Rock Health Digital Health Luminary Award and Top 50 in Digital Health Award. In academic and industry roles, he has led teams to build and commercialize software-enabled remote patient monitoring platforms and electronic health record AI-guided knowledge extraction tools, most recently as Head of Medical with 100Plus (acquired by Connect America) and as co-founder of Evidently.

Over the last 20 years, he has had several dozen leadership and clinical practice guideline author roles in the Heart Rhythm Society (HRS), American Heart Association, American College of Cardiology, and European Society of Cardiology. He was the Founding Chair of HRX 2022, a new clinical and industry meeting by HRS dedicated to remote patient monitoring and cardiovascular diagnostics. He is a Trustee of the International Society for Holter and Noninvasive Electrocardiology, member of the American Heart Association Health Technology Advisory Committee, Board Advisor of Connect America, and Co-Founder of Evidently.


Salary from Employment: iRhythm Technologies
Stocks – Privately Held: 100Pluss
Research (Contracted Grants for PIs and Named Investigators Only): Bristol-Myers Squibb, Bayer Healthcare Pharmaceuticals, Sanofi